A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)

Trial Profile

A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Breast cancer; Early breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CREATE-X
  • Most Recent Events

    • 07 Nov 2014 Planned End Date changed from 1 Jan 2015 to 30 Jun 2017 as reported by University Hospital Medical Information Network - Japan.
    • 14 Dec 2013 First tolerability analysis presented at the 36th Annual San Antonio Breast Cancer Symposium.
    • 27 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top